相关实验视频
Updated: Jul 12, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
ANGPTL3 (血管蛋白类型3) 首选居住在人体循环中的高密度脂蛋白上,影响其活动
Jordan M Kraaijenhof1, Tycho R Tromp1, Nick S Nurmohamed1,2
1Department of Vascular Medicine Amsterdam University Medical Centers, Location AMC Amsterdam The Netherlands.
血管类蛋白3 (ANGPTL3) 与HDL和LDL结合,但其脂酶抑制活性在与LDL结合时是最高的. 这一发现影响了对脂质代谢和心血管疾病风险的理解.
科学领域:
- 生物化学 生物化学
- 脂质代谢 脂质代谢是什么
- 心血管研究研究心血管研究
背景情况:
- 血管类蛋白3 (ANGPTL3) 是脂质代谢的关键调节剂,抑制脂蛋白脂酶和内皮脂酶.
- ANGPTL3与脂蛋白的结合及其对脂酶活性的影响在很大程度上仍未被描述.
研究的目的:
- 研究ANGPTL3与低密度脂蛋白 (LDL) 和高密度脂蛋白 (HDL) 颗粒的相关性.
- 确定脂蛋白结合如何影响ANGPTL3的脂酶抑制活性.
- 探索ANGPTL3度,HDL参数和发生冠状动脉疾病之间的关系.
主要方法:
- 再组合的ANGPTL3被与来自健康志愿者的分离的LDL和HDL分子化.
- 血ANGPTL3分布测量在健康的志愿者和一个HDL缺乏患者使用快速蛋白质液态染色学.
- 用棕色脂肪细胞中的3H-三酸盐评估了脂酶活性和细胞吸收.
- 在EPIC-诺福克研究中分析了血ANGPTL3,高密度胆固醇,大型高密度胆固醇颗粒和发病冠状动脉疾病之间的关联.
主要成果:
- 发现ANGPTL3与LDL和HDL颗粒相结合.
- 在健康个体中,大约75%的脂蛋白相关的ANGPTL3在HDL分片中被发现.
- 当与LDL (25.4%的减少) 和HDL (21.4%的减少) 结合时,ANGPTL3显著抑制了脂酶活性,但当不结合时却没有.
- 较高的血ANGPTL3度与高密度胆固醇,大密度胆固醇颗粒和发生的冠状动脉疾病有关.
结论:
- ANGPTL3 首选与 HDL 颗粒结合.
- 然而,当与LDL颗粒结合时,ANGPTL3表现出其最高的脂酶抑制活性.
- 这些发现表明ANGPTL3,脂蛋白和脂质代谢之间存在复杂的相互作用,这对心血管健康有影响.
更多相关视频
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
07:37Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening
Published on: May 13, 2020
相关概念视频
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Atherosclerosis III: Management
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...